These findings demonstrate a strong dependency on RTK signalling pathways, ERBB, MAPK and PI3K/AKT, in which EML4-ALK+positive NSCLC cells adapt to overcome ALK inhibition. Here, EML4 is linked to non-small cell lung carcinoma.